Dr David Propper

Dr David Propper

Centre: Centre for Cancer & Inflammation
Senior Lecturer
This email address is being protected from spambots. You need JavaScript enabled to view it.

My focus is detailed translational trials in pancreatic cancer.

Research Details

I am lead for GI trials with a focus on pancreatic cancer. I work with scientists within the BCI in crosscutting themes targeting the tumour microenvironment. These approaches include immune therapies, stem cell, stromal and vascular targeting. A major emphasis is on GCP level detailed biomarker studies in early phase trials. In the laboratory, we use a variety of preclinical models and clinically derived material to study effects of therapies in pancreatic cancer.

Profile

I am a Senior Lecturer and Consultant Medical Oncologist based at Barts Cancer Institute and St Bartholomew’s Hospital.

Funding

  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity

Key Publications

Middleton G, Palmer D.H, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw V.E, Wadsley J, Valle J.W, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos J.P, 2017. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective randomised double-blind multicentre phase 2 trial. The Lancet. Oncology 18 486-499.

Nijhuis A, Thompson H, Adam J, Parker A, Gammon L, Lewis A, Bundy J.G, Soga T, Jalaly A, Propper D, Jeffery R, Suraweera N, McDonald S, Thaha M.A, Feakins R, Lowe R, Bishop C.L, Silver A, 2017. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Human molecular genetics 26 1552-1564.

Propper D, Jones K, Anthoney D.A, Mansoor W, Ford D, Eatock M, Agarwal R, Inatani M, Saito T, Abe M, Evans T.R, 2016. Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC cancer 16 779.

Suraweera N, Mouradov D, Li S, Jorissen R.N, Hampson D, Ghosh A, Sengupta N, Thaha M, Ahmed S, Kirwan M, Aleva F, Propper D, Feakins R.M, Vulliamy T, Elwood N.J, Tian P, Ward R.L, Hawkins N.J, Xu Z.Z, Molloy P.L, Jones I.T, Croxford M, Gibbs P, Silver A, Sieber O.M, 2016. Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. Oncotarget 7 36474-36488.

My focus is detailed translational trials in pancreatic cancer.

See other researchers working on:

Clinical Trials Pancreas
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.